PDCD1 and hepatocellular carcinoma: Compared with patients with advanced HCC receiving regorafenib, PD-1 antibody, and HAIC as second-line treatment, there is no significant benefit in ORR (11–20%, recist1.1), DCR (58–66%), and PFS (3.0–4.9 months) (8, 19–21).